<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102489</url>
  </required_header>
  <id_info>
    <org_study_id>BP101-HV02</org_study_id>
    <nct_id>NCT03102489</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP101 After Multiple Doses Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivix LLX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivix LLX</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy
      Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, placebo-controlled study of the safety, tolerability,
      pharmacokinetics and pharmacodynamics of BP101 after multiple doses administration in healthy
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate frequency, seriousness, and severity of adverse events, including events of dose-limiting toxicity in healthy volunteers receiving different doses of BP101 compared to placebo after multiple administrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BP101 maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter of maximum plasma concentration (Cmax) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP101 area under the concentration versus time curve (AUC)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter area under the plasma concentration versus time curve (AUC) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP101 time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter time to maximum plasma concentration (Tmax) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP101 half-life time (T1/2)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter of plasma half-life time (T1/2) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function Index (FSFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function Index (FSFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Distress Scale-Revised score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Distress Scale-Revised (FSDS-R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Distress Scale-Revised score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Distress Scale-Revised (FSDS-R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function questionnaire score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function (FSF) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function questionnaire score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function (FSF) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Arizona Sexual Experience Scale score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Arizona Sexual Experience Scale (ASEX) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Arizona Sexual Experience Scale score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Arizona Sexual Experience Scale (ASEX) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypoactive Sexual Desire Disorder(HSDD)</condition>
  <arm_group>
    <arm_group_label>BP101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with BP101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP101</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>BP101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women aged from 18 to 40, inclusive.

          -  Verified diagnosis &quot;healthy&quot;: absence gastrointestinal, hepatic, renal,
             cardiovascular, endocrine, central nervous system, ear, nose, throat (ENT) and
             gynecological disorders (performed standard clinical, laboratory and instrumental
             assessments did not reveal any disorders).

          -  Body mass index (BMI) within range from 18.5 to 30 kg/m^2.

          -  Subject consent not to intake alcohol during the entire study period; negative alcohol
             breath test at screening and before start of Investigational Product administration.

          -  Negative pregnancy test result at screening and before start of Investigational
             Product administration.

          -  Consent to use adequate methods of contraception throughout the study.

          -  Normal regular menstrual cycle of 28 +/- 7 days duration for at least 6 months before
             study enrollment.

          -  Women with stable sexual partner.

        Exclusion Criteria:

          -  Chronic cardiovascular, respiratory, neuroendocrine, genitourinary systems disorders,
             as well as gastrointestinal, hepatic, renal, blood, and ENT disorders (including acute
             and chronic rhinitis, sinusitis, and others).

          -  Gynecological disorders (polycystic ovary syndrome, mommas, endometriosis,
             inflammatory diseases and others).

          -  Positive cervical cytology Papanicolaou (PAP) test in medical anamnesis within 12
             months before screening.

          -  Lab abnormalities (blood hematology and biochemistry and urinalysis) at screening.

          -  Electrocardiogram (ECG) abnormalities at screening, and before start of
             Investigational Product administration.

          -  Systolic blood pressure in a sitting position below 100 mm Hg or above 140 mm Hg;
             and/or diastolic pressure below 60 mm Hg or above 90 mm Hg at screening and before
             start of Investigational Product administration.

          -  Heart rate less than 60 beats/min or more than 90 beats/min at screening, and before
             start of Investigational Product administration.

          -  Signs of malignant neoplasms in medical history, during the examination at any time
             prior to start of Investigational Product administration.

          -  Psychiatric disorders (including any form of schizophrenia, epilepsy, bipolar
             affective disorder and others), intake of psychotropic agents.

          -  Chronic pain syndromes (including chronic pelvic pain syndrome).

          -  Acute infections within 4 weeks before screening.

          -  Regular intake of medications (including nonprescription drugs, vitamins, and
             Supplements) within 2 weeks before screening.

          -  Intake of more than 5 units of alcohol per week (1 unit of alcohol is equivalent to
             0.5 liter of beer, 200 ml wine or 30 ml of spirit (pure alcohol)) or historical
             information about alcoholism, substance abuse, prescription drug abuse.

          -  Smoking more than 10 cigarettes a day.

          -  Pregnancy or breastfeeding, positive urine pregnancy at screening and before the start
             of Investigational Product administration.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female healthy volunteers</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniil Nemenov, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ivix LLX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research center Eco-Safety LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

